Kristen Jackson, MD
Endocrinology, Diabetes & Metabolism · Danbury, CTNPI 1255727558
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,444 of the $4,255 with a category attached, or 80.9%. 30 manufacturers reported payments, led by Novo Nordisk at 30.6% of the total. Reporting peaked in 2023 at $1,339 and has fallen 89.9% since, to $135 in 2025.
Across 164 payments — averaging $25.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$487
- Abbott$462
- Boehringer Ingelheim$231
- Dexcom, Inc.$191
- Amgen$156
- plus $1K from 24 others
What the payments were for
- Travel & lodging$79719%
- Food & beverage$3,44481%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 8 | $1,303 |
| Lilly USA, LLC | 20 | $487 |
| Abbott | 38 | $462 |
| Boehringer Ingelheim | 11 | $231 |
| Dexcom, Inc. | 9 | $191 |
| Amgen | 4 | $156 |
| Xeris Pharmaceuticals, Inc. | 8 | $151 |
| Amneal Pharmaceuticals LLC | 7 | $132 |
| Radius Health, Inc. | 6 | $124 |
| Tandem Diabetes Care, Inc. | 4 | $116 |
| Sanofi-aventis U.S. LLC | 4 | $87 |
| Averitas Pharma Inc. | 3 | $81 |
| Pfizer | 4 | $79 |
| AbbVie(2 entities) | 5 | $78 |
| Antares Pharma, Inc. | 5 | $78 |
| AstraZeneca(2 entities) | 4 | $72 |
| Kyowa Kirin, Inc. | 3 | $56 |
| Mannkind Corporation | 3 | $52 |
| Halozyme Inc | 3 | $45 |
| Embecta Corp. | 2 | $44 |
| Insulet Corporation | 2 | $37 |
| BETA Bionics, Inc. | 2 | $32 |
| Avvisto Therapeutics, LLC | 2 | $27 |
| Sequel Med Tech, LLC | 1 | $26 |
| IBSA Pharma Inc. | 1 | $22 |
| Cequr Corporation | 1 | $22 |
| Alvogen Inc | 1 | $20 |
| Novartis | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
How this compares
$4,255 in reported general payments places this provider in the 70th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 97 | $160,548 |
| MounjaroTirzepatide | 86 | $142,174 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $99,494 |
| OzempicSemaglutide | 48 | $86,943 |
| TrulicityDulaglutide | 46 | $86,104 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $68,501 |
| JardianceEmpagliflozin | 51 | $64,175 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 30 | $42,163 |
| JanuviaSitagliptin Phosphate | 22 | $34,946 |
| FarxigaDapagliflozin Propanediol | 25 | $33,104 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $32,052 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $28,979 |
| RybelsusSemaglutide | 11 | $25,708 |
| Novolog FlexpenInsulin Aspart | 44 | $22,600 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $487 | $228,278132 claims |
| Novo NordiskOzempic, Rybelsus | $1,303 | $112,65159 claims |
| Boehringer IngelheimJardiance | $231 | $64,17551 claims |
| AstraZenecaFarxiga | $72 | $33,10425 claims |
| AbbVieSynthroid | $78 | $4,86548 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $132 | $3,714292 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Danbury
- Anna ZiganshinaDanbury$7K
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.